## Titre
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma

## Protocole ID
CA224-047

## ClinicalTrials.gov ID
NCT03470922

## Type(s) de cancer
Mélanome

## Phase
Phase II

## Stade
Métastatique

## Type étude
Traitement

## Médicament
Relatlimab avec Nivolumab

## Institution
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL  
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  
3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2

## Ville
Montréal

## Investigateur principal
Dr Wilson Miller

## Coordonnateur
Naeem Iqbal  
514-340-8222

## Statut
Fermé

## But étude
The purpose of this study is to determine whether Nivolumab in combination with Relatlimab is more effective than Nivolumab by itself in treating unresectable Melanoma or Melanoma that has spread

## Critères d'éligibilité
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system  
- Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma  
- Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses

## Critères d'exclusion
- Participants must not have active brain metastases or leptomeningeal metastases  
- Participants must not have ocular melanoma  
- Participants must not have an active, known, or suspected autoimmune disease  
- Other protocol defined inclusion/exclusion criteria could apply